u7vd2tmj

Property	Value
?:abstract	Background: There is an ongoing critical need to improve therapeutic strategies for COVID-19 pneumonia, particularly in the most severely affected patients. Adult mesenchymal stem cell (MSC) infusions have the potential to benefit critically ill patients with acute respiratory syndrome SARS-COV-2 infection, but clinical data supporting efficacy are lacking. Methods: We conducted a case-control study of critically ill patients with laboratory-confirmed COVID-19, severe acute respiratory distress syndrome (ARDS). To evaluate clinical responsiveness in the most critically ill patient we examined outcomes in a sub-group of those requiring extracorporeal membrane oxygenation (ECMO) support. Patients (n=9) were administered with up to 3 infusions of intravenous (IV) MSCs and compared to a local ECMO control group (n=31). The primary outcome was safety, and the secondary outcomes were all-cause mortality (or rate of hospital discharge), cytokine levels, and viral clearance. Findings: MSC infusions (12 patients) were well tolerated and no side effects occurred. Of ECMO patients receiving MSC infusions, 2 out of 9 died (22.2%; 95%CI: 2.8%, 60.0%) compared with a mortality of 15 of 31 (48.4%; 95%CI: 30.2%, 66.9%; p = 0.25) in the ECMO control group. Isolated plasma exosomes containing the SARS-COV-2 Spike protein decreased after MSC infusions between day 14 or 21 after administration (p=0.003 and p=0.005, respectively) and was associated with a decrease in COVID-19 IgG Spike protein titer at same time points (p = 0.006 and p=0.007, respectively). Control ECMO patients receiving convalescent plasma did not clear COVID-19 IgG over the same time frame. Interpretation: Together these findings suggest that MSC IV infusion is well tolerated in patients with a broad range of severity including the most severe COVID-19 ARDS requiring ECMO. These data also raise the possibility that MSCs, in addition to exerting an immunomodulatory effect, contribute to viral clearance and strongly support the conduct of randomized placebo-controlled trial.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/u7vd2tmj_hasAnnotation_C0027627> <https://research.tib.eu/covid-19/entity/u7vd2tmj_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Kaushal%2C_S.%3B_Khan%2C_A.%3B_Deatrick%2C_K.%3B_Ng%2C_D._K.%3B_Snyder%2C_A.%3B_Shah%2C_A.%3B_Caceres%2C_L._V.%3B_Bacallao%2C_K.%3B_Bembea%2C_M.%3B_Everett%2C_A.%3B_Zhu%2C_J.%3B_Kaczorowski%2C_D.%3B_Madathil%2C_R.%3B_Tabatabai%2C_A.%3B_Rosenthal%2C_G.%3B_Brooks%2C_A.%3B_Longsomboon%2C_B.%3B_Mishra%2C_R.%3B_Saha%2C_P.%3B_Desire%2C_Y.%3B_Saltzman%2C_R.%3B_Hankey%2C_K._G.%3B_Arias%2C_S._A.%3B_Ayoade%2C_F.%3B_Tovar%2C_J._A.%3B_Lamazares%2C_R.%3B_Gershengorn%2C_H._B.%3B_Magali%2C_F._J.%3B_Loebe%2C_M.%3B_Mullins%2C_K.%3B_Gunasekaran%2C_M.%3B_Karakeshishyan%2C_V.%3B_Jayaweera%2C_D._T.%3B_Atala%2C_A.%3B_Ghodsizad%2C_A.%3B_Hare%2C_J._M.>
?:doi	10.1101/2020.10.15.20122523
?:doi	<https://research.tib.eu/covid-19/entity/10.1101/2020.10.15.20122523>
?:license	medrxiv
?:pdf_json_files	document_parses/pdf_json/7d493ad7ea2bc4f7be42e4e37da8e91b2b110e6e.json
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/u7vd2tmj_HAS_C5391442_AFFECTS_C1257975>
?:sha_id	<https://research.tib.eu/covid-19/entity/7d493ad7ea2bc4f7be42e4e37da8e91b2b110e6e>
?:source	MedRxiv; WHO
?:title	Intravenous Mesenchymal Stem Cells in Extracorporeal Oxygenation Patients with Severe COVID-19 Acute Respiratory Distress Syndrome
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-10-20

Property

Value

?:abstract

Background: There is an ongoing critical need to improve therapeutic strategies for COVID-19 pneumonia, particularly in the most severely affected patients. Adult mesenchymal stem cell (MSC) infusions have the potential to benefit critically ill patients with acute respiratory syndrome SARS-COV-2 infection, but clinical data supporting efficacy are lacking. Methods: We conducted a case-control study of critically ill patients with laboratory-confirmed COVID-19, severe acute respiratory distress syndrome (ARDS). To evaluate clinical responsiveness in the most critically ill patient we examined outcomes in a sub-group of those requiring extracorporeal membrane oxygenation (ECMO) support. Patients (n=9) were administered with up to 3 infusions of intravenous (IV) MSCs and compared to a local ECMO control group (n=31). The primary outcome was safety, and the secondary outcomes were all-cause mortality (or rate of hospital discharge), cytokine levels, and viral clearance. Findings: MSC infusions (12 patients) were well tolerated and no side effects occurred. Of ECMO patients receiving MSC infusions, 2 out of 9 died (22.2%; 95%CI: 2.8%, 60.0%) compared with a mortality of 15 of 31 (48.4%; 95%CI: 30.2%, 66.9%; p = 0.25) in the ECMO control group. Isolated plasma exosomes containing the SARS-COV-2 Spike protein decreased after MSC infusions between day 14 or 21 after administration (p=0.003 and p=0.005, respectively) and was associated with a decrease in COVID-19 IgG Spike protein titer at same time points (p = 0.006 and p=0.007, respectively). Control ECMO patients receiving convalescent plasma did not clear COVID-19 IgG over the same time frame. Interpretation: Together these findings suggest that MSC IV infusion is well tolerated in patients with a broad range of severity including the most severe COVID-19 ARDS requiring ECMO. These data also raise the possibility that MSCs, in addition to exerting an immunomodulatory effect, contribute to viral clearance and strongly support the conduct of randomized placebo-controlled trial.

is ?:annotates of